Patent: 10,189,822
✉ Email this page to a colleague
Summary for Patent: 10,189,822
Title: | Heterocyclic modulators of lipid synthesis |
Abstract: | Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders. |
Inventor(s): | Oslob; Johan D. (Menlo Park, CA), McDowell; Robert S. (Menlo Park, CA), Johnson; Russell (Menlo Park, CA), Yang; Hanbiao (Menlo Park, CA), Evanchik; Marc (Menlo Park, CA), Zaharia; Cristiana A. (Menlo Park, CA), Cai; Haiying (Menlo Park, CA), Hu; Lily W. (Menlo Park, CA), Duke; Gregory (Menlo Park, CA), Ohol-Gupta; Yamini (Menlo Park, CA), Heuer; Timothy Sean (Menlo Park, CA), O\'Farrell; Marie (Menlo Park, CA) |
Assignee: | 3-V Biosciences, Inc. (Menlo Park, CA) |
Application Number: | 15/558,813 |
Patent Claims: | see list of patent claims |
Details for Patent 10,189,822
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2035-03-19 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2035-03-19 |
Eli Lilly And Company | CYRAMZA | ramucirumab | Injection | 125477 | 04/21/2014 | ⤷ Try a Trial | 2035-03-19 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |